We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

47 hedge funds and large institutions have $156M invested in Protalix BioTherapeutics in 2013 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3.41% more ownership

Funds ownership: 0% → 3.41% (+3.4%)

74% less call options, than puts

Call options by funds: $599K | Put options by funds: $2.31M

Holders
47
Holders Change
+47
Holders Change %
–
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
47
Increased
–
Reduced
–
Closed
–
Calls
$599K
Puts
$2.31M
Net Calls
-$1.72M
Net Calls Change
-$1.72M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$50.9M +$55M +1,037,349 New
Allianz Asset Management
2
Allianz Asset Management
Germany
$34.9M +$37.7M +710,720 New
Baillie Gifford & Co
3
Baillie Gifford & Co
United Kingdom
$23.5M +$25.4M +478,006 New
BA
4
BlackRock Advisors
Delaware
$9.06M +$9.79M +184,561 New
CCM
5
Camber Capital Management
Massachusetts
$7.37M +$7.96M +150,000 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$5.89M +$6.36M +119,909 New
MMH
7
Menora Mivtachim Holdings
Israel
$5.36M +$5.79M +109,108 New
DCM
8
DAFNA Capital Management
California
$4.26M +$4.61M +86,811 New
First Eagle Investment Management
9
First Eagle Investment Management
New York
$2.46M +$2.65M +50,000 New
JRJ
10
Jeffrey R. Jay
$1.96M +$2.12M +39,901 New
BG
11
BlackRock Group
United Kingdom
$1.36M +$1.47M +27,667 New
State of New Jersey Common Pension Fund D
12
State of New Jersey Common Pension Fund D
New Jersey
$1.18M +$1.27M +24,000 New
State of Wisconsin Investment Board
13
State of Wisconsin Investment Board
Wisconsin
$982K +$1.06M +20,000 New
U
14
UBS
Switzerland
$943K +$1.02M +19,210 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$934K +$1.01M +19,029 New
MNA
16
Manning & Napier Advisors
New York
$784K +$847K +15,971 New
OAM
17
Oberweis Asset Management
Illinois
$540K +$584K +11,000 New
ERSOT
18
Employees Retirement System of Texas
Texas
$447K +$483K +9,100 New
Northern Trust
19
Northern Trust
Illinois
$401K +$433K +8,169 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$322K +$348K +6,561 New
Nomura Holdings
21
Nomura Holdings
Japan
$266K +$286K +5,386 New
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$243K +$263K +4,950 New
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$234K +$239K +4,510 New
Morgan Stanley
24
Morgan Stanley
New York
$233K +$252K +4,753 New
Goldman Sachs
25
Goldman Sachs
New York
$198K +$214K +4,041 New
1
2

PLX Hedge Fund Activity: Q2 2013 in Review

47 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2013, worth a combined $156M.

Buyers outnumbered sellers: 47 funds opened new PLX positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.

  • 47 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $156M of Protalix BioTherapeutics stock for Q2 2013.
  • 47 funds opened new Protalix BioTherapeutics positions in Q2 2013 and 0 closed out, a net change of +47 holders.

Based on aggregated 13F filings for Q2 2013.